Comparison · NCT00004978-sae
rIL-2 vs No rIL-2: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. rIL-2 vs No rIL-2: serious adverse events. Trial comparisons, record NCT00004978-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00004978-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.225 | 0.208 | 0.243 | wilson | |
| Risk in group 2 | 0.188 | 0.171 | 0.205 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0373 | 0.0125 | 0.0619 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.2 | 1.06 | 1.35 | log | |
| Odds ratio, group 1 over group 2 | 1.26 | 1.08 | 1.46 | log | |
| Number needed to harm, for one more participant with a serious adverse event on rIL-2 than on No rIL-2 | 26.8 | 16.1 | 79.9 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | rIL-2 | Subcutaneous recombinant interleukin-2 (rIL-2) therapy | 466 | 2,071 | EG000 |
| Group 2 | No rIL-2 | Control group - no study-assigned medication | 383 | 2,040 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Grade 4 events were reportable from randomization through study end (15 November 2008), irrespective of whether patient was taking a study treatment.
Source ClinicalTrials.gov
Trial
- Title
- An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy
- NCT number
- NCT00004978
- Phases
- PHASE3
- Conditions
- HIV Infections
- Interventions
- Recombinant interleukin-2 (rIL-2)
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Results first posted
- 2011-04-25
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00004978?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00004978-sae